logo

Evaxion Biotech A/S (EVAX)



Trade EVAX now with
  Date
  Headline
9/21/2022 5:50:42 AM Evaxion Reports Enrolment Of First Patient In Phase 2b Trial Of EVX-01
5/11/2022 7:40:24 AM Evaxion Biotech Q1 Net Loss $5.8 Mln Or $0.25/Shr Vs Loss $4.1 Mln Or $0.23/Shr Last Year
4/26/2022 8:49:47 AM Evaxion To Utilize Personalis' ImmunoID Platform To Evaluate Efficacy Of Combination Therapy For Late-Stage Melanoma
3/22/2022 6:38:25 AM Evaxion Biotech FY Net Loss $24.5 Mln Or $1.26/Shr Vs Loss $15.0 Mln Or $0.97/Shr Last Year
10/25/2021 5:45:18 AM Evaxion To Collaborate With MSD On Phase 2b Trial With EVX-01
8/12/2021 6:51:15 AM Evaxion Biotech Q2 Net Loss $6.8 Mln Or $0.36/Shr Vs Loss $3.6 Mln Or $0.24/shr Last Year
7/8/2021 6:05:44 AM Evaxion Biotech Reports Results From Phase 1/2a Trials Of EVX-01 In Metastatic Melanoma And EVX-02 In Adjuvant Melanoma
5/26/2021 8:37:06 AM Evaxion Biotech Appoints Lars Holtug To Board